Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAStem cell injection for acute respiratory distress syndrome
ChiCTR2200061436Phase 2Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of CAStem cells in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: All-cause mortality rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
CAStem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2200061436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061436.